These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12449148)

  • 41. Smoldering, asymptomatic stage 1, and indolent myeloma.
    Greipp PR
    Curr Treat Options Oncol; 2000 Jun; 1(2):119-26. PubMed ID: 12057049
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Palliative treatment of painful bone metastases from non-Hodgkin lymphoma with disodium pamidronate.
    Pistevou-Gombaki K; Eleftheriadis N; Sofroniadis I; Makris P; Kouloulias V
    J Exp Clin Cancer Res; 2002 Sep; 21(3):429-32. PubMed ID: 12385590
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Management of bone lesions in multiple myeloma].
    Hata H; Mitsuya H
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1072-6. PubMed ID: 16912524
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.
    Menssen HD; Sakalová A; Fontana A; Herrmann Z; Boewer C; Facon T; Lichinitser MR; Singer CR; Euller-Ziegler L; Wetterwald M; Fiere D; Hrubisko M; Thiel E; Delmas PD
    J Clin Oncol; 2002 May; 20(9):2353-9. PubMed ID: 11981007
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bisphosphonates for Patients Diagnosed With Multiple Myeloma.
    Mhaskar R; Djulbegovic B
    JAMA; 2018 Oct; 320(14):1483-1484. PubMed ID: 30326511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Prospective study of pamidronate disodium in treatment of Paget's disease of bone].
    Zhang ZL; Meng XW; Xing XP; Wang O; Xia WB; Li M; Jiang Y; Fu Y; Zhou XY
    Zhonghua Yi Xue Za Zhi; 2003 Oct; 83(19):1653-6. PubMed ID: 14642096
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Influence of bisphosphonate combined with chemotherapy on bone mineral density of patients with multiple myeloma].
    Zhang X; Chang CK; Zhang Z; Zhao YS; Xiao C; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1135-8. PubMed ID: 23114134
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease.
    Wang Y; Lin B
    PLoS One; 2012; 7(9):e44868. PubMed ID: 23028650
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group].
    García-Sanz R; Alegre A; Capote FJ; Hernández JM; Rosiñol L; Rubia Jde L; Sureda A; Arriba Fd; Bargay J; Díaz Mediavilla J; García-Laraña J; Lahuerta JJ; Mateos MV; Prósper F; San Miguel J; Bladé J;
    Med Clin (Barc); 2010 Mar; 134(6):268-78. PubMed ID: 19863972
    [No Abstract]   [Full Text] [Related]  

  • 51. Myeloma bone disease and treatment options.
    Yeh HS; Berenson JR
    Eur J Cancer; 2006 Jul; 42(11):1554-63. PubMed ID: 16797971
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Medical Research Council Myeloma IX Trial: new clinical insights on the anticancer effects of zoledronic acid in patients with multiple myeloma.
    Berenson JR
    Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):2-4. PubMed ID: 22130220
    [No Abstract]   [Full Text] [Related]  

  • 53. Bisphosphonate complications including osteonecrosis of the jaw.
    Mehrotra B; Ruggiero S
    Hematology Am Soc Hematol Educ Program; 2006; ():356-60, 515. PubMed ID: 17124083
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic approaches to myeloma bone disease: an evolving story.
    Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
    Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transient response of myeloma clone to pamidronate therapy.
    Corso A; Astori C; Orlandi E; Zappasodi P; Arcaini L; Bernasconi C
    Haematologica; 1999 Aug; 84(8):759-60. PubMed ID: 10457421
    [No Abstract]   [Full Text] [Related]  

  • 57. [Clinical observation on effect of combined therapy of pamidronati sodium and shenfu injection in treating multiple myeloma caused ostealgia].
    Ma M
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2004 Jan; 24(1):67-8. PubMed ID: 14976895
    [No Abstract]   [Full Text] [Related]  

  • 58. [The affection of bisphosphonates combined with chemotherapy on bone metabolism index in multiple myeloma].
    Zhang X; Chang CK; Wu LY; Zhang Z; Zhou LY; Xiao C; Li X
    Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):660-3. PubMed ID: 22339822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Myeloma: diagnosis complications and supportive care.
    Morgan G
    Hematology; 2012 Apr; 17 Suppl 1():S109-11. PubMed ID: 22507795
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Two bedridden patients with bone metastases from breast cancer effectively treated with pamidronate therapy].
    Kokufu I; Taniguchi H; Kim YH; Fukuda K; Yamamoto M; Yano T; Yamada K; Kitano H
    Gan To Kagaku Ryoho; 2000 Oct; 27(11):1751-4. PubMed ID: 11057329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.